弹力蛋白特异性分子MRI追踪前列腺癌进展中肿瘤-间质界面ECM重塑
本研究在SCID小鼠原位前列腺癌模型中,每周使用基于钆的弹力蛋白特异性探针ESMA行3.0T MRI,连续追踪6周。结果显示,对比后信号从基线1517±151逐步升高至第6周3400±411(2.2倍,P<0.001),且外周肿瘤区域弹力蛋白含量(2.95±1.63%)显著高于中心区域(1.00±0.40%,P<0.008)。提示弹力蛋白可作为监测基质驱动型肿瘤进展的候选影像生物标志物。
要点
- ESMA增强MRI可无创追踪前列腺癌进展中弹力蛋白沉积的动态过程。
- 弹力蛋白主要聚集于肿瘤外周侵袭前沿,提示用于定位肿瘤-间质界面。
- 肿瘤边缘弹力蛋白含量约为中央区的3倍,阅片时需关注外周强化区。
核心结论
- ESMA增强分子MRI可捕获前列腺癌进展中弹力蛋白沉积的纵向动态变化,外周优势分布与侵袭前沿ECM重塑一致,提示弹力蛋白可作为基质驱动型肿瘤进展的候选影像生物标志物。
研究设计与样本
- 原位小鼠模型研究,将人PC3前列腺癌细胞原位植入SCID小鼠腹侧前列腺叶,样本量n=6。
- 3.0T MRI平台,每周经静脉注射钆基弹力蛋白特异性探针ESMA,剂量0.2 mmol/kg,连续6周,对比前后均行信号强度定量。
- 组织学验证采用Elastica-van Gieson染色、免疫荧光、Western blot分析及LA-ICP-MS空间钆定量。
关键影像表现/征象
- 对比后信号强度由基线的1517±151逐步升高至第6周的3400±411,增幅2.2倍(P<0.001),第2至第3周间强化最明显。
- 弹力蛋白分布呈空间异质性,外周肿瘤区域弹力蛋白含量(2.95±1.63%)显著高于中央区(1.00±0.40%,P<0.008)。
- LA-ICP-MS显示钆浓度与组织学弹力蛋白含量强相关(R²=0.88,P<0.001),Western blot在所有肿瘤中均检测到原弹力蛋白表达。
诊断标准与关键数值
- 与外周肿瘤区域弹力蛋白含量2.95±1.63%对应的对比后信号呈优势强化,中央区为1.00±0.40%,组间差异P<0.008。
- 钆浓度与组织学弹力蛋白含量的相关性R²=0.88(P<0.001),支持ESMA探针结合的特异性。
- 第2至第3周对比后信号增幅最显著,可作为随访中重点观察的时间窗口。
临床应用与阅片要点
- 阅片时应重点关注肿瘤外周区域的对比后信号变化,该区域对应弹力蛋白富集的肿瘤-间质界面。
- 弹力蛋白特异性分子探针可为临床提供基质重塑相关的功能信息,超出常规MRI形态学评估能力。
- 连续监测中第2至第3周的信号变化可作为肿瘤进展评估的潜在观察节点。
局限性
- 样本量为n=6,来源仅为人PC3原位小鼠模型,尚未在临床样本中验证。
- 每6周重复注射钆基探针的长期安全性及累积剂量问题尚未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Extracellular matrix (ECM) remodeling is a hallmark of tumor progression, yet the longitudinal dynamics of elastin accumulation during prostate cancer (PCa) development remain unknown. This study aimed to longitudinally track elastin remodeling during PCa progression using elastin-specific molecular MRI (ESMA) in an orthotopic mouse model and to characterize the spatial heterogeneity of elastin deposition at the tumor-stroma interface.
MATERIALS AND METHODS: Human PC3 prostate cancer cells were orthotopically implanted into the ventral prostate lobe of SCID mice (n=6). Weekly MRIs were performed over 6 weeks at 3.0 Tesla using the gadolinium-based elastin-specific probe ESMA (0.2 mmol/kg intravenous weekly). Signal intensity (SI) was quantified before and after contrast administration. Findings were validated by Elastica-van Gieson staining, immunofluorescence, Western blot analysis, and laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) for spatial gadolinium mapping.
RESULTS: Postcontrast SI increased progressively from 1517±151 at baseline to 3400±411 at week 6 (2.2-fold increase, P <0.001), with the most pronounced enhancement between weeks 2 and 3. Elastin distribution was spatially heterogeneous: peripheral tumor regions contained significantly more elastin (2.95±1.63%) than central areas (1.00±0.40%, P <0.008), indicating preferential ECM remodeling at the tumor-stroma interface. LA-ICP-MS demonstrated a strong correlation between gadolinium concentration and histologic elastin content ( R2 =0.88, P <0.001), and Western blot detected tropoelastin expression in all tumors.
CONCLUSION: ESMA-enhanced molecular MRI captures the longitudinal dynamics of elastin accumulation during PCa progression. Progressive elastin deposition, concentrated at the tumor periphery, is consistent with active ECM remodeling at the invasive front and suggests elastin as a candidate imaging biomarker for monitoring matrix-driven tumor progression.
引用
- Kader, Mangarova, Gödde, et al. Elastin-Specific Molecular Magnetic Resonance Imaging Reveals Spatiotemporal Extracellular Matrix Remodeling at the Tumor-Stroma Interface During Prostate Cancer Progression. Invest Radiol. 2026. PMID: 42452893. doi:10.1097/RLI.0000000000001302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。